In this study, we investigated the effects and molecular mechanisms of 2-phenylbenzimidazole-5-sulphonic acid (PBSA), an ultraviolet B protecting agent used in sunscreen lotions and moisturizers, on ovarian cancer cell responses and tumour angiogenesis. PBSA treatment markedly blocked mitogen-induced invasion through down-regulation of matrix metalloproteinase (MMP) expression and activity in ovarian cancer SKOV-3 cells. In addition, PBSA inhibited mitogen-induced cell proliferation by suppression of cyclin-dependent kinases (Cdks), but not cyclins, leading to pRb hypophosphorylation and G 1 phase cell cycle arrest. These anti-cancer activities of PBSA in ovarian cancer cell invasion and proliferation were mediated by the inhibition of mitogen-activated protein kinase kinase 3/6-p38 mitogen-activated protein kinase (MKK3/6-p38 MAPK ) activity and subsequent down-regulation of MMP-2, MMP-9, Cdk4, Cdk2 and integrin β1, as evidenced by treatment with p38 MAPK inhibitor SB203580. Furthermore, PBSA suppressed the expression and secretion of vascular endothelial growth factor in SKOV-3 cells, leading to inhibition of capillary-like tubular structures in vitro and angiogenic sprouting ex vivo. Taken together, our results demonstrate the pharmacological effects and molecular targets of PBSA on modulating ovarian cancer cell responses and tumour angiogenesis, and suggest further evaluation and development of PBSA as a promising chemotherapeutic agent for the treatment of ovarian cancer. K E Y W O R D S 2-phenylbenzimidazole-5-sulphonic acid, angiogenesis, ovarian cancer, p38 MAPK 1 | INTRODUC TI ON Ovarian cancer is the second leading cause of mortality among the gynaecologic cancers. 1 High mortality rates of ovarian cancer patients may be due in part to a lack of highly sensitive detection methods or effective therapeutics against metastatic and recurrent phenotypes. 2 Dysregulated activation or overexpression of cell signalling-related molecules including receptor tyrosine kinases (RTKs) | 2689 KIM et al.
and integrins mediates aberrant activation of their downstream signalling pathways that triggers uncontrolled and imbalanced responses, suggesting the rational strategy and pharmacological efficacy of RTK/integrin-targeted therapeutics for the treatment of ovarian cancer. [3] [4] [5] In addition, matrix metalloproteinases (MMPs), which degrade extracellular matrix (ECM) and cellular components in the tissue microenvironment, are closely associated with cancer cell growth and progression as well as normal tissue remodelling. 6, 7 High expression and activity of MMPs have been reported to contribute to aggressive phenotypes and poor survival of ovarian cancer. 8, 9 However, inhibition of MMP activity without sufficient knowledge about substrate specificity or physiological roles in cancer biology has been disappointing in various cancer clinical trials. 10 Therefore, intensive investigations of cellular and molecular networks underlying the progression of ovarian cancer may provide insights into effective therapeutic targets and strategies for the prevention and treatment of cancer.
2-Phenylbenzimidazole-5-sulphonic acid (PBSA) has widely been used as a sunscreen agent to protect skin from ultraviolet (UV) radiation, resulting in reduction of sunburn, early skin ageing and skin cancer. In parallel to the protective effect against UV-induced cyclobutane pyrimidine dimers, PBSA has also been reported to generate a variety of free radicals and exhibit photosensitizing activity, raising the possibility of phototoxic damage to cellular components including DNA, proteins and lipids. [11] [12] [13] [14] Although the potential side effects and risks of PBSA to ecosystem as well as human health have been proposed in several safety and toxicity studies, chronic exposure to PBSA did not significantly induce pathological changes in the liver or gonads of rainbow trout, a common toxicity model organism. 15 Furthermore, the phototoxic potential of PBSA could be reduced by complexation with hydroxypropyl-β-cyclodextrin. 16 However, the effects and molecular mechanisms of PBSA on cell responses including invasion, adhesion and proliferation have not yet been elucidated in detail. In this study, we report the regulatory roles and molecular mechanisms of PBSA in ovarian cancer cell fates including invasion and proliferation, and tumour-derived angiogenic responses.
F I G U R E 1 PBSA inhibits cell invasion and adhesion. A, The chemical structure of PBSA. B, Cell invasion, (C) adhesion and (D) viability assays were performed as described in Materials and methods. Quiescent SKOV-3 cells were pre-treated with PBSA for 30 min, followed by 10% FBS stimulation for 16 h (invasion), 2 h (adhesion) or 24 h (viability). Results from at least three independent experiments (mean ± SD) are presented as (B) the numbers of invasive cells, (C) the numbers of adherent cells or (D) the percentage of viable cells of total cell counts. Statistical significance is indicated (**P < .01, compared with 10% FBS-treated cells) 2 | MATERIAL S AND ME THODS
| Cell culture conditions
Human ovarian cancer cells (SKOV-3) from American Type Culture Collection (ATCC) were grown in 10% foetal bovine serum-Dulbecco's modified Eagle's medium (FBS-DMEM) (Hyclone Laboratories).
Human umbilical vein endothelial cells (HUVECs) were purchased from Lonza and used between passages 4 and 6 for all experiments.
Cells were cultured in EGM-2 ® BulletKit media, according to the manufacturer's instructions (Lonza).
| Reagents
2-Phenylbenzimidazole-5-sulphonic acid (PBSA) was obtained from Sigma-Aldrich. The structure of PBSA is presented in Figure 1A . The following chemical agents and antibodies were purchased from commercial sources: p38 MAPK inhibitor, SB203580 (Cayman Chemical); anti-phospho-Src (Y416), anti-Src, anti-phospho-ERK (T202/Y204), anti-phospho-Akt (S473), anti-phospho-p70 S6K (T421/S424), antiphospho-MKK3 (S189)/MKK-6 (S207), anti-MKK3, anti-MKK6, anti-phospho-p38 MAPK (T180/Y182), anti-phospho-pRb (S780), anti-phospho-pRb (S807/S811), anti-MMP-2 and anti-MMP-9 (Cell Signaling); anti-phospho-FAK (Y397) and anti-FAK (BD Biosciences); anti-ERK, anti-Akt, anti-p70 S6K , anti-38 MAPK , anti-TIMP-2, anti-Cdk4, ant-Cdk2, anti-cyclin D, anti-cyclin E, anti-integrin β1, anti-EGFR, anti-FGFR-1, anti-VEGFR-2, anti-actin and mouse and rabbit IgGhorseradish peroxidase conjugates (Santa Cruz Biotechnology Inc).
| RNA purification and reverse transcriptasepolymerase chain reaction (RT-PCR)
Subconfluent SKOV-3 cells in 100 mm dishes (1 × 10 6 cells/well, SPL Life Sciences Co.) were serum-starved for 24 hours in basal DMEM to synchronize cells in G 1 /G 0 phase of the cell cycle and pre-treated with PBSA (10, 50 μmol/L) for 30 minutes, followed by 10% FBS stimulation for 24 hours. In some experiments, quiescent cells were pre-treated with PBSA or SB203580 for 30 minutes, followed by 10% FBS stimulation for 12 hours. After stimulation, cells were thoroughly rinsed with phosphate-buffered saline (PBS, pH 7.4) to remove any residual PBSA or SB203580, and further incubated with 10% FBS for another 12 hours until the end of the 24 hours time-point.
Total RNA was purified with PureHelix ™ RNA extraction solution (Nanohelix Co.). Integrity of RNA was checked by agarose gel electrophoresis and ethidium bromide staining. One microgram of RNA was used as template for each reverse transcriptase (RT)-mediated polymerase chain reaction (PCR) using 1 st Strand cDNA Synthesis kit (BioAssay Co.). Primers for PCR were synthesized by Bioneer Corporation. Primer sequences were as follows: matrix metalloproteinases-2 (MMP-2), forward 5′-GCTCAGATCCGTGGTGAGAT-3′ and reverse 5′-GGTGCTGGCTGAGTAGATCC-3′; MMP-9, forward 5′-CAACATCACCTATTGGATCC-3′ and reverse 5′-TGGGTGTAG AGTCTCTCCCT-3′; VEGF, forward 5′-TCGGGCCTCCGAAACC ATGA-3′ and reverse 5′-CCTGGTGAGAGATCTGGTTC-3′; glyceraldehyde-3-phosphate dehydrogenase (GAPDH), forward 5′-GAAGGTGAAGGTCGGAGTC-3′ and reverse 5′-GAAGATGG TGATGGGATTTC-3′. Bands of interest were integrated and quantified by the use of NIH ImageJ version 1.51j8 software.
| Western blot analysis
Quiescent SKOV-3 cells in 6-well plates (5 × 10 4 cells/well, SPL Life Sciences Co.) were pre-treated with PBSA for 30 minutes, followed by 10% FBS stimulation for different time-points, as indicated.
Cells were rinsed twice with ice-cold PBS and lysed by incubation in 50 mmol/L Tris-HCl (pH 7.4), 150 mmol/L NaCl, 1 mmol/L EDTA, 1% Triton X-100, 10% glycerol, 0.5 μg/mL leupeptin, 1 μg/ mL pepstatin A, 10 μg/mL aprotinin, 100 μg/mL AEBSF, 1 mmol/L sodium orthovanadate, 25 mmol/L sodium fluoride and 80 mmol/L β-glycerophosphate for 30 minutes at 4ºC. Cell lysates were clarified at 12 500 g for 20 minutes at 4ºC, and the supernatants were subjected to Western blot analysis as described previously. 17 All
Western blots are representative of at least three independent experiments. Bands of interest were integrated and quantified by the use of NIH ImageJ version 1.51j8 software.
| Cell viability and proliferation
Quiescent SKOV-3 cells or HUVECs were pre-treated with PBSA at different concentrations (2-50 μmol/L) for 30 minutes in the presence or absence of SB203580 (5 μmol/L) as indicated, and further incubated with 10% FBS or EGM-2 ® BulletKit for 24 hours. In some experiments, quiescent SKOV-3 cells were pre-treated with PBSA for 30 minutes, followed by 10% FBS stimulation for 12 hours. After stimulation, cells were rinsed with PBS to remove any residual PBSA and further incubated with 10% FBS for another 12 hours. Cell viability was determined by a Muse ™ cell analyser using cell count and viability assay kit (Merck Millipore), and the cell proliferation was quantified as previously described. 18 The results from triplicate determinations (mean ± standard deviation) are presented as the percentage of viable cells of total cell counts or the fold increase of the untreated controls.
| Cell cycle analysis
Quiescent SKOV-3 cells were pre-treated with PBSA (50 µmol/L) for 
| Cell adhesion assay
Subconfluent SKOV-3 cells were detached with trypsin-EDTA and allowed to recover in 10% FBS-DMEM for 1 hour at 37ºC with gentle rocking. After recovery, cells were collected and resuspended in serum-free DMEM. The cell suspension was pre-treated with PBSA (10, 50 μmol/L) for 30 minutes, and followed by 10% FBS stimulation.
Cells were plated on 96-well plates (1.5 × 10 4 cells/well) and further incubated for 2 hours at 37ºC. After incubation, unattached cells were removed by washing the wells three times with PBS. Attached cells were fixed with methanol and then stained with 0.04% Giemsa staining solution (Sigma-Aldrich). Cells were photographed and counted.
The results (mean ± standard deviation) are presented as the numbers of adherent cells. 19
| Cell invasion assay
The upper side of the transwell insert (Costar Ⓡ , 6.5 mm diameter insert, 8 μm pore size) (Corning Inc) was coated with 50 μL of 1 mg/mL Matrigel Ⓡ (BD Biosciences) diluted in serum-free DMEM.
Aliquots (100 μL) of cells (6 × 10 5 cells/mL) resuspended in serumfree DMEM were added to the upper compartment of the Matrigelcoated transwell, and 600 μL of serum-free DMEM was added to the lower compartment. After culture for 2 hours, cells were pretreated with PBSA (2-50 μmol/L) for 30 minutes in the presence or absence of SB203580 (5 μmol/L), followed by 10% FBS stimulation for 16 hours. The inserts were fixed with methanol, and using a cotton-tipped swab, the non-invasive cells were removed from the top of the membrane. After staining with 0.04% Giemsa staining solution, the numbers of invasive cells (mean ± standard deviation) were determined from six different fields using ×200 objective magnification. 20
| Zymogram analysis
Activities of MMPs were measured by zymography. 21 
| Tube formation assay
Tube formation assay was performed to examine the ability of con- 
| Statistical analysis
Statistical analysis was performed using Student's t test and was based on at least three different experiments. The results were considered to be statistically significant when P < .05.
| RE SULTS

| PBSA inhibits cell invasion through the regulation of MMP expression and activity
Cell invasion, migration and adhesion are closely associated with cancer progression and aggressiveness. 6 We first examined the ability of PBSA to regulate cell invasion and adhesion in p53-deficient SKOV-3 ovarian cancer cells. PBSA treatment dose-dependently inhibited mitogen-induced cell invasion and adhesion (Figure 1B ,C) and did not alter cell viability ( Figure 1D ), indicating the potential of PBSA in the regulation of cell invasion and adhesion without cytotoxicity. In addition, our initial experiments demonstrated that PBSA significantly inhibited the invasion of p53 wild-type ovarian cancer cells including A2780, OVTOKO and TOV-21G to levels similar to that observed in SKOV-3 cells (data not shown). We next examined the changes in expression levels and activities of MMPs, which play important roles in cell invasion, migration, adhesion and proliferation by degrading extracellular matrix (ECM) components and cell surface proteins. 6, 7 The levels of MMP-2 activity in the conditioned media from cell cultures were shown to be higher than those of MMP-9 (Figure 2A) , consistent with previous findings. 4 Integrated density values were normalized to untreated controls. Statistical significance is indicated (*P < .05, **P < .01, compared with 10% FBS-treated cells) reversible ( Figure 3D ). Collectively, these findings indicate that PBSA possesses anti-invasive, anti-adhesive and anti-proliferative activity against ovarian cancer SKOV-3 cells. 
| PBSA inhibits cell proliferation through the regulation of cell cycle-related proteins
| PBSA inhibits integrin β1 expression and p38 MAPK phosphorylation
| Anti-cancer activities of PBSA are mediated by the inactivation of p38 MAPK -dependent signalling pathway
To directly examine the contribution of inactivation of p38 MAPK to the anti-cancer activity of PBSA, we investigated the changes in cell invasion and proliferation in the presence or absence of SB203580, an inhibitor of p38 MAPK pathway, in mitogen-stimulated SKOV-3 cells. SB203580 treatment mimicked the inhibitory effect of PBSA on mitogen-stimulated cell invasion and proliferation (Figure 5A,B ).
SB203580 treatment also suppressed mitogen-induced expression of MMP-9, MMP-2, Cdk4, Cdk2 and integrin β1 ( Figure 5C ). These data are consistent with previous cell invasion and cell cycle-related protein expression experiments ( Figures 2C, 3C and 4A) . The addition of SB203580 did not significantly enhance the ability of PBSA to inhibit cell invasion and proliferation, suggesting that PBSA and SB203580 may share similar mechanisms of action in the regulation of cellular responses. Collectively, these findings demonstrate that inactivation of p38 MAPK mediates anti-invasive and anti-proliferative activities of PBSA against ovarian cancer SKOV-3 cells.
F I G U R E 6 PBSA inhibits endothelial tube formation through the downregulation of VEGF. A, Quiescent SKOV-3 cells were pre-treated with PBSA for 30 min, followed by 10% FBS stimulation for (left panel) 24 h or (right panel) 48 h. RT-PCR and ELISA analyses were performed as described in Materials and methods. B, HUVEC tube formation assay was performed using conditioned media from SKOV-3 cell culture treated as described above (A, left panel) . Values represent the mean ± SD of at least three independent experiments. Statistical significance is indicated (*P < .05, **P < .01, compared with 10% FBS-treated cells). C, Quiescent HUVECs were incubated for 24 h in complete media containing growth factors with or without PBSA. Results from at least three independent experiments are presented as the fold increase of the untreated controls (left panel) or the percentage of viable cells of total cell counts (right panel)
| PBSA inhibits endothelial cell tube formation in vitro and angiogenic sprouting ex vivo through p38 MAPK -dependent regulation of VEGF expression and secretion in ovarian cancer cells
In the tumour microenvironment, cancer cells produce and secrete numerous biologically active molecules such as growth factors and cytokines, which are closely associated with angiogenic and metastatic responses. [28] [29] [30] We analysed the changes in the expression and secretion of a key angiogenic factor VEGF in PBSA-treated SKOV-3 cells. As shown in Figure 6A , PBSA treatment significantly The p38 MAPK -dependent signalling pathway is closely involved in inflammation and cancer development as well as tissue homoeostasis. 37 Identification of the key roles and regulatory mechanisms of p38 MAPK in a number of physiological and pathological processes may provide therapeutic perspectives and strategies for preclinical and clinical applications. 38, 39 Recent studies demonstrate that activation and expression of p38 MAPK play important roles in regulating ovarian cancer cell responses including invasion and proliferation. 40, 41 Thus, it is important to note that selective blockade of p38 MAPK activation and expression provides key information for the treatment of ovarian cancer.
In this study, we demonstrate that PBSA negatively regulates 
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